uniQure N.V.

NASDAQ:QURE

Biotechnology

Healthcare
$20.30 -2.34%

-$1.13 today

Market cap
$1.42B
Beta
1.00
P/E (TTM)
-14.1
EPS (TTM)
-$3.33
52W Low $8.73High $71.50

Volume 1.13M

Average 1.75M

QURE Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

uniQure N.V.NASDAQ: QURE

Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026

Cash & equivalents falls 35.6% from a year ago

Cash & equivalents stood at $139.99M at the end of Q1 FY2026, down 35.6% from a year earlier and up 74.5% from the prior quarter. Over 3 fiscal years it compounded at -29.4% a year.

Context

  • Cash & equivalents amounted to 18.0% of total assets at the end of Q1 FY2026, down 17.9 pp from a year earlier.
  • Cash & equivalents increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -35.6% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$139.99M+74.5% QoQ
Last fiscal yearDec 2025
$80.24M-49.5% YoY
Year agoMar 2025
$217.23M-35.6% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-35.6%——
1 year-49.5%——
3-year CAGR-29.4%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
80.24M USD
Year-over-year change
-49.5%
4-year CAGR
-38.4%

Cash & Equivalents vs competitors

How QURE compares with its peers on the latest reported figures

  • QURE's Mar 2026 cash & equivalents of $139.99M is the 2nd highest of the 8 companies compared; the peer median is $71.54M.
  • Its year-over-year change of -35.6% is the 5th highest of 8, against a peer median of -0.4%.
  • Cash & equivalents amounts to 18.0% of total assets for QURE, versus a peer median of 17.4%.
QURE Competitors Peer median
Cash & Equivalents for QURE and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
RAREUltragenyx Pharmaceutical Inc.Mar 2026$175M +37.7%+48.3%13.5%
QUREuniQure N.V.Mar 2026$139.99M -35.6%-29.4%18.0%
NGNENeurogene Inc.Mar 2026$124.16M +75.4%+8.2%47.2%
FDMT4D Molecular Therapeutics, Inc.Mar 2026$72.49M -45.7%+4.8%14.1%
MGTXMeiraGTx Holdings plcMar 2026$71.54M +7.5%-17.1%29.2%
RCKTRocket Pharmaceuticals, Inc.Mar 2026$49.61M -0.4%-18.0%17.4%
VYGRVoyager Therapeutics, Inc.Mar 2026$43.31M -42.1%-12.9%19.7%
RGNXREGENXBIO Inc.Mar 2026$15.23M -88.3%-29.2%4.5%
Peer median (excluding QURE) $71.54M-0.4%-12.9%17.4%

Competitors are the stored peer set for QURE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents556.26M228.01M241.36M158.93M80.24M
Short-term Investments0124.83M376.53M208.59M542.3M
Net Receivables58.77M102.38M4.19M5.88M5.86M
Inventory06.92M12.02M00
Other Current Assets2.68M2.81M2.66M7.61M7.08M
Total Current Assets628.24M476.77M651.85M390.29M655.99M
Property, Plant & Equipment (Net)69.08M83.26M75.34M34.07M26.33M
Goodwill27.63M25.58M26.38M22.41M25.36M
Intangible Assets62.69M58.78M60.48M71.04M72.79M
Long-term Investments039.98M2.18M27.46M30.24M
Tax Assets15.65M14.53M12.28M9.86M8.65M
Other Non-current Assets5.9M6.06M3.18M1.4M5.56M
Total Non-current Assets180.94M228.19M179.84M166.25M168.92M
Total Assets809.18M704.96M831.69M556.54M824.91M
Account Payables2.5M10.98M6.59M7.23M5.17M
Short-term Debt5.77M8.38M003.86M
Tax Payables00000
Deferred Revenue13.01M11.12M0020.49M
Other Current Liabilities2.87M28.23M45.91M19.12M23.46M
Total Current Liabilities36.76M75.92M73.68M40.05M62.92M
Long-term Debt100.96M102.79M101.75M51.32M522.9M
Deferred Tax Liabilities12.91M8.26M7.54M7.04M7.97M
Deferred Revenue (Non-current)00000
Other Non-current Liabilities33.78M10.27M412.74M453.73M22.39M
Total Non-current Liabilities176.64M153.04M550.34M523.24M563.09M
Total Liabilities213.4M228.96M624.02M563.29M626.01M
Common Stock2.8M2.84M2.88M2.95M3.69M
Retained Earnings(455.14M)(581.93M)(890.41M)(1.13B)(1.33B)
Accumulated OCI(28.86M)(58.29M)(53.55M)(52.8M)(58.22M)
Other Stockholders Equity00000
Minority Interest00000
Total Equity595.78M476.01M207.67M(6.75M)198.9M
Total Debt135.72M142.89M138.41M66.06M536.59M
Net Debt(420.53M)(85.12M)(102.95M)(92.87M)456.35M

uniQure N.V.

NASDAQ:QURE

Intrinsic Alpha fair value

Locked

Current Price

$20.30

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.